PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.
Identifieur interne : 001294 ( PubMed/Checkpoint ); précédent : 001293; suivant : 001295PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.
Auteurs : D J Doudet [Canada] ; M L Cornfeldt ; C R Honey ; A W Schweikert ; R C AllenSource :
- Experimental neurology [ 0014-4886 ] ; 2004.
English descriptors
- KwdEn :
- Animals, Binding, Competitive (physiology), Dihydroxyphenylalanine (analogs & derivatives), Disease Models, Animal, Dopamine (metabolism), Female, Humans, Macaca fascicularis, Macaca mulatta, Male, Parkinsonian Disorders (diagnostic imaging), Parkinsonian Disorders (therapy), Pigment Epithelium of Eye (cytology), Pigment Epithelium of Eye (metabolism), Pigment Epithelium of Eye (transplantation), Putamen (diagnostic imaging), Putamen (metabolism), Putamen (surgery), Raclopride (metabolism), Radioligand Assay, Recovery of Function (drug effects), Recovery of Function (physiology), Tomography, Emission-Computed, Treatment Outcome, Up-Regulation (drug effects), Up-Regulation (physiology).
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , metabolism : Dopamine, Raclopride.
- cytology : Pigment Epithelium of Eye.
- diagnostic imaging : Parkinsonian Disorders, Putamen.
- drug effects : Recovery of Function, Up-Regulation.
- metabolism : Pigment Epithelium of Eye, Putamen.
- physiology : Binding, Competitive, Recovery of Function, Up-Regulation.
- surgery : Putamen.
- therapy : Parkinsonian Disorders.
- transplantation : Pigment Epithelium of Eye.
- Animals, Disease Models, Animal, Female, Humans, Macaca fascicularis, Macaca mulatta, Male, Radioligand Assay, Tomography, Emission-Computed, Treatment Outcome.
Abstract
Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [18F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [11C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.
DOI: 10.1016/j.expneurol.2004.06.009
PubMed: 15380486
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15380486Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.</title><author><name sortKey="Doudet, D J" sort="Doudet, D J" uniqKey="Doudet D" first="D J" last="Doudet">D J Doudet</name><affiliation wicri:level="1"><nlm:affiliation>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia, Vancouver, BC, Canada V6T 2B5. ddoudet@interchange.ubc.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Cornfeldt, M L" sort="Cornfeldt, M L" uniqKey="Cornfeldt M" first="M L" last="Cornfeldt">M L Cornfeldt</name></author><author><name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C R" last="Honey">C R Honey</name></author><author><name sortKey="Schweikert, A W" sort="Schweikert, A W" uniqKey="Schweikert A" first="A W" last="Schweikert">A W Schweikert</name></author><author><name sortKey="Allen, R C" sort="Allen, R C" uniqKey="Allen R" first="R C" last="Allen">R C Allen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15380486</idno><idno type="pmid">15380486</idno><idno type="doi">10.1016/j.expneurol.2004.06.009</idno><idno type="wicri:Area/PubMed/Corpus">001322</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001322</idno><idno type="wicri:Area/PubMed/Curation">001322</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001322</idno><idno type="wicri:Area/PubMed/Checkpoint">001322</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001322</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.</title><author><name sortKey="Doudet, D J" sort="Doudet, D J" uniqKey="Doudet D" first="D J" last="Doudet">D J Doudet</name><affiliation wicri:level="1"><nlm:affiliation>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia, Vancouver, BC, Canada V6T 2B5. ddoudet@interchange.ubc.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Cornfeldt, M L" sort="Cornfeldt, M L" uniqKey="Cornfeldt M" first="M L" last="Cornfeldt">M L Cornfeldt</name></author><author><name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C R" last="Honey">C R Honey</name></author><author><name sortKey="Schweikert, A W" sort="Schweikert, A W" uniqKey="Schweikert A" first="A W" last="Schweikert">A W Schweikert</name></author><author><name sortKey="Allen, R C" sort="Allen, R C" uniqKey="Allen R" first="R C" last="Allen">R C Allen</name></author></analytic><series><title level="j">Experimental neurology</title><idno type="ISSN">0014-4886</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Binding, Competitive (physiology)</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Female</term><term>Humans</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Male</term><term>Parkinsonian Disorders (diagnostic imaging)</term><term>Parkinsonian Disorders (therapy)</term><term>Pigment Epithelium of Eye (cytology)</term><term>Pigment Epithelium of Eye (metabolism)</term><term>Pigment Epithelium of Eye (transplantation)</term><term>Putamen (diagnostic imaging)</term><term>Putamen (metabolism)</term><term>Putamen (surgery)</term><term>Raclopride (metabolism)</term><term>Radioligand Assay</term><term>Recovery of Function (drug effects)</term><term>Recovery of Function (physiology)</term><term>Tomography, Emission-Computed</term><term>Treatment Outcome</term><term>Up-Regulation (drug effects)</term><term>Up-Regulation (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Raclopride</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Pigment Epithelium of Eye</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinsonian Disorders</term><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Recovery of Function</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Pigment Epithelium of Eye</term><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Binding, Competitive</term><term>Recovery of Function</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Pigment Epithelium of Eye</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Humans</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Male</term><term>Radioligand Assay</term><term>Tomography, Emission-Computed</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [18F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [11C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15380486</PMID><DateCreated><Year>2004</Year><Month>09</Month><Day>21</Day></DateCreated><DateCompleted><Year>2004</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-4886</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Experimental neurology</Title><ISOAbbreviation>Exp. Neurol.</ISOAbbreviation></Journal><ArticleTitle>PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>361-8</MedlinePgn></Pagination><Abstract><AbstractText>Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [18F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [11C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doudet</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia, Vancouver, BC, Canada V6T 2B5. ddoudet@interchange.ubc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornfeldt</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Honey</LastName><ForeName>C R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Schweikert</LastName><ForeName>A W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Exp Neurol</MedlineTA><NlmUniqueID>0370712</NlmUniqueID><ISSNLinking>0014-4886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2C598205QX</RegistryNumber><NameOfSubstance UI="C043437">fluorodopa F 18</NameOfSubstance></Chemical><Chemical><RegistryNumber>430K3SOZ7G</RegistryNumber><NameOfSubstance UI="D020891">Raclopride</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004295" MajorTopicYN="N">Dihydroxyphenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010857" MajorTopicYN="N">Pigment Epithelium of Eye</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020891" MajorTopicYN="N">Raclopride</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>06</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15380486</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2004.06.009</ArticleId><ArticleId IdType="pii">S0014488604002407</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Allen, R C" sort="Allen, R C" uniqKey="Allen R" first="R C" last="Allen">R C Allen</name><name sortKey="Cornfeldt, M L" sort="Cornfeldt, M L" uniqKey="Cornfeldt M" first="M L" last="Cornfeldt">M L Cornfeldt</name><name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C R" last="Honey">C R Honey</name><name sortKey="Schweikert, A W" sort="Schweikert, A W" uniqKey="Schweikert A" first="A W" last="Schweikert">A W Schweikert</name></noCountry><country name="Canada"><noRegion><name sortKey="Doudet, D J" sort="Doudet, D J" uniqKey="Doudet D" first="D J" last="Doudet">D J Doudet</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001294 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001294 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15380486
|texte= PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15380486" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |